E Anckaert1, M Öktem2, A Thies3, M Cohen-Bacrie4, N M P Daan5, J Schiettecatte6, C Müller7, D Topcu2, A Gröning3, F Ternaux4, C Engel8, S Engelmann9, C Milczynski7. 1. Laboratory of Hormonology and Tumour Markers, Universitair Ziekenhuis Brussel, Free University of Brussels (VUB), Brussels, Belgium. Electronic address: ellen.anckaert@uzbrussel.be. 2. Duzen Laboratories Group, Tunus Cad. No. 95, Kavaklidere, Ankara, Turkey. 3. MVZ wagnerstibbe für Laboratoriumsmedizin and Pathologie GmbH, Georgstraße 50, 30159 Hannover, Germany. 4. Laboratoire Eylau Saint Didier, 55, rue Saint Didier, 75116 Paris, France. 5. Department of Reproductive Medicine and Gynecology, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands. 6. Laboratory of Hormonology and Tumour Markers, Universitair Ziekenhuis Brussel, Free University of Brussels (VUB), Brussels, Belgium. 7. Limbach Laboratory, Medical Care Center, Im Breitspiel 15, 69126 Heidelberg, Germany. 8. Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany. 9. Roche Diagnostics GmbH, Sandhofer Str. 116, 68305 Mannheim, Germany.
Abstract
OBJECTIVES: Anti-Müllenria hormone (AMH) is an established biomarker for assessing ovarian reserve and predicting response to controlled ovarian stimulation. Its routine clinical use is hampered by the variability and low-throughput of available enzyme-linked immunosorbent assays (ELISA). The presented study examined if a fully automated AMH electrochemiluminescence assay (ECLIA; Elecsys® AMH assay, Roche Diagnostics) was suitable for measuring AMH levels in healthy women and in those diagnosed with polycystic ovary syndrome (PCOS). DESIGN AND METHODS: Five European laboratories evaluated the Elecsys® AMH assay independently under routine conditions over eight months. Within-run imprecision, repeatability, intermediate precision, linearity and functional sensitivity were assessed. The Elecsys® AMH assay was compared to a manual ELISA microtiter plate format test (AMH Gen II ELISA, modified version; Beckman Coulter Inc.) using 1729 routine serum samples. AMH reference intervals were determined in 887 healthy women with regular menstrual cycle aged 20–50 years, and 149 women diagnosed with PCOS. RESULTS: The fully automated Elecsys® AMH assay showed excellent precision, linearity, and functional sensitivity. The coefficient of variation was 1.8% for repeatability and 4.4% for intermediate precision. Values measured with the Elecsys® AMH assay were highly correlated with the manual ELISA method (modified version) but 24–28% lower. Reference intervals showed the expected AMH decline with age in healthy women and increased AMH levels in women with PCOS. CONCLUSIONS: The Elecsys® AMH assay demonstrated good precision under routine conditions, and is suitable for determining AMH levels in serum and lithium-heparin plasma.
OBJECTIVES: Anti-Müllenria hormone (AMH) is an established biomarker for assessing ovarian reserve and predicting response to controlled ovarian stimulation. Its routine clinical use is hampered by the variability and low-throughput of available enzyme-linked immunosorbent assays (ELISA). The presented study examined if a fully automated AMH electrochemiluminescence assay (ECLIA; Elecsys® AMH assay, Roche Diagnostics) was suitable for measuring AMH levels in healthy women and in those diagnosed with polycystic ovary syndrome (PCOS). DESIGN AND METHODS: Five European laboratories evaluated the Elecsys® AMH assay independently under routine conditions over eight months. Within-run imprecision, repeatability, intermediate precision, linearity and functional sensitivity were assessed. The Elecsys® AMH assay was compared to a manual ELISA microtiter plate format test (AMH Gen II ELISA, modified version; Beckman Coulter Inc.) using 1729 routine serum samples. AMH reference intervals were determined in 887 healthy women with regular menstrual cycle aged 20–50 years, and 149 women diagnosed with PCOS. RESULTS: The fully automated Elecsys® AMH assay showed excellent precision, linearity, and functional sensitivity. The coefficient of variation was 1.8% for repeatability and 4.4% for intermediate precision. Values measured with the Elecsys® AMH assay were highly correlated with the manual ELISA method (modified version) but 24–28% lower. Reference intervals showed the expected AMH decline with age in healthy women and increased AMH levels in women with PCOS. CONCLUSIONS: The Elecsys® AMH assay demonstrated good precision under routine conditions, and is suitable for determining AMH levels in serum and lithium-heparin plasma.
Authors: B Meczekalski; A Czyzyk; M Kunicki; A Podfigurna-Stopa; L Plociennik; G Jakiel; M Maciejewska-Jeske; K Lukaszuk Journal: J Endocrinol Invest Date: 2016-06-14 Impact factor: 4.256
Authors: Marleen van den Berg; Marloes van Dijk; Julianne Byrne; Helen Campbell; Claire Berger; Anja Borgmann-Staudt; Gabriele Calaminus; Uta Dirksen; Jeanette F Winther; Sophie D Fossa; Desiree Grabow; Victoria L Grandage; Marry M van den Heuvel-Eibrink; Melanie Kaiser; Tomas Kepak; Leontien C Kremer; Jarmila Kruseova; Claudia E Kuehni; Cornelis B Lambalk; Flora E van Leeuwen; Alison Leiper; Dalit Modan-Moses; Vera Morsellino; Claudia Spix; Peter Kaatsch; Eline van Dulmen-den Broeder Journal: JMIR Res Protoc Date: 2018-09-14
Authors: Laura Melado; Barbara Lawrenz; Junard Sibal; Emmanuel Abu; Carol Coughlan; Alfredo T Navarro; Human Mousavi Fatemi Journal: Front Endocrinol (Lausanne) Date: 2018-11-27 Impact factor: 5.555
Authors: Helen Jopling; Allen Yates; Nicholas Burgoyne; Katharine Hayden; Christopher Chaloner; Lesley Tetlow Journal: Endocrinol Diabetes Metab Date: 2018-07-18
Authors: Stamatina Iliodromiti; Barbara Salje; Didier Dewailly; Craig Fairburn; Renato Fanchin; Richard Fleming; Hang Wun Raymond Li; Krzysztof Lukaszuk; Ernest Hung Yu Ng; Pascal Pigny; Teddy Tadros; Joseph van Helden; Ralf Weiskirchen; Scott M Nelson Journal: Hum Reprod Date: 2017-08-01 Impact factor: 6.918